查詢結果分析
相關文獻
- Ho-166-Acetylacetonate-Lipiodol核醫藥物研製及其做為肝癌體內輻射治療之細胞實驗評估
- 長期葉酸消耗對人類肝癌細胞株HepG2之細胞生長繁殖及形態變化的影響
- 建立Acid Phosphatase酵素分析方法大量篩選天然物之抗癌藥
- 乙型轉型因子對於肝癌細胞死亡的調控與機制之研究
- The Combined Effect of Colchicine and Radiation on Human Hepatoma HA22T/VGH Cells
- 抑制人類肝癌細胞株乙型肝炎表面抗原分泌的天然物研究
- 維生素K[feb0]單獨或併用游離輻射對人類肝癌細胞的影響
- Histamine-Induced Increases in Intracellular Free Ca[fec7] Levels in Hepatoma Cells
- The Involvement of PI3-K/Akt-Dependent UP-Regulation of Mcl-1 in the Prevention of Apoptosis of Hep3B Cells by Interleukin-6
- Solamargine對肝癌細胞之作用機轉及其具器官導向之超微粒製劑在抗肝細胞腫瘤上的應用
頁籤選單縮合
題 名 | Ho-166-Acetylacetonate-Lipiodol核醫藥物研製及其做為肝癌體內輻射治療之細胞實驗評估=Preparation and in Vitro Evaluation Using Holmium-166-Acetylacetonate-Lipiodol as a Potential Agent for the Internal Radiation Therapy of Hepatocellular Carcinoma |
---|---|
作 者 | 周鳳英; 戚謹文; 衛元耀; 蔣淑娟; 謝明學; 雷永耀; | 書刊名 | 放射治療與腫瘤學 |
卷 期 | 4:3 1997.09[民86.09] |
頁 次 | 頁185-193 |
分類號 | 418.94 |
關鍵詞 | 肝癌細胞; 核醫藥劑; Ho-166-AcAc-lipiodol; Hepatoma cells; Radiopharmaceuticals; |
語 文 | 中文(Chinese) |
中文摘要 | 目的:本研究之目的是以中子活化之 Ho-166 研製肝癌治療核醫藥劑, 測試藥物 之穩定性及對肝癌細胞之作用。 材料與方法: 將研製之 Ho-165-acetylacetonate ( Ho-165-AcAc )藥物於清華大學水池 式反應器進行中子照射,使 Ho-165 轉換成釋放高能β輻射之 Ho-166 核種。以多頻道能譜 分析儀分析藥物核種強度及純度。 所得之 Ho-166-AcAc 以碘化罌粟油攜帶之,並於血清中 測試其穩定性,以培養之人類肝癌細胞( HepG2 cells )探討藥物對肝癌細胞之作用。 結果:Ho-165-AcAc 置於反應器之垂直照射管中照射 10 小時, 所生成之 Ho-166-AcAc 放 射比活性可達 16-18 mCi/50 mg,經 120 小時血清中測試結果顯示 Ho-166-AcAc-lipiodol 中約有 98 %的 Ho-166 保存在其油相之中。 HepG2 細胞在 Ho-165-AcAc-lipiodol 處理 24 小時後, 顯微鏡下可見有大量 Ho-165-AcAc-lipiodol 脂球積聚其中, 此時細胞內的 Ho-165-AcAc 量為 1.3 μ g/10 �� cells。由施藥時 Ho-166-AcAc-lipiodol 之放射比活 性可以估算得細胞中 Ho-166-AcAc-lipiodol 之放射活性。 結論:Ho-166-acetylacetonate-lipiodol 攜帶高能β輻射釋出核種,於血清之穩定性高, 細胞實驗結果顯示, Ho-165-AcAc-lipiodol 可為肝癌細胞所大量攝入,此體外研究提供未 來體內實驗之基本資料,此 Ho-166-AcAc-lipiodol 藥物應可提供肝癌-新的體內輻射治療 機會。 |
英文摘要 | Objective: The objective of this research was to synthesize and prepare radiopharmaceuticals containing neutron-activated Ho-166. The in vitro stability of Ho-166-radiopharmaceuticals was tested, and the interaction of the radiopharmaceuticals with hepatoma cells was investigated. Materials and Methods: In order to generate Ho-166, the non-radioactive Ho-165-acetylacetonate (Ho-165-AcAc) was prepared and irradiated in the Tsing Hua Open-Pool Reactor. Multiple channel analyzer was used for analysis of the radioactivity and the purity of the Ho-166-AcAc. Lipiodol was used as a carrier of Ho-166-AcAc. The stability of Ho-166-AcAc-lipiodol in serum was tested. The interaction of Ho-165-AcAc-lipiodol with human hepatoma cells (HepG2 cells) was investigated. Result: In this study, the prepared Ho-165-AcAc samples were irradiated in the nuclear reactor for up to 10 hr and yielded 16-18mCi/50mg of specific activity. In addition, in vitro analysis of the stability of Ho-166-AcAc-lipiodol in plasma revealed a 98% retention of Ho-166 in the Ho-166-AcAc-lipiodol after 120 hr. In vitro treatment of HepG2 cells for 24 hr with Ho-165-AcAc-lipiodol resulted in a retention of 1.3 μ g of Ho-165-AcAc in 10 �� cells. Thus, from the specific activity of Ho-166-AcAc-lipiodol the potential radioactivity of Ho-166 in HepG2 cells can be evaluated. Conclusion: Ho-166-AcAc-lipiodol contained sufficient high energy β emitter and has a high stability in serum. In vitro cell culture analysis showed that large amount of Ho-165-AcAc-lipiodol can be uptake by hepatoma cells. Results of this In vitro study provided important basic information for future development and In vitro tests. The Ho-166-AcAc-lipiodol has potential for future hepatoma therapy. |
本系統中英文摘要資訊取自各篇刊載內容。